Cullinan Oncology LLC • CGEM

Capital at risk.

About Cullinan Oncology LLC
Ticker
info
CGEM
Trading on
info
NASDAQ
ISIN
info
US2300311063
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Nadim Ahmed M.S.
Headquarters
info
One Main Street, Cambridge, MA, United States, 02142
Employees
info
109
Website
info
https://cullinantherapeutics.com
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$1.3B
P/E ratio
info
-
EPS
info
-$3.11
Dividend Yield
info
0.00%
Beta
info
0.02
Forward P/E ratio
info
6.74
EBIDTA
info
$-221M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.3B
Average daily volume
info
0.9M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
6.74
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
25.86
Price to book
info
4.11
Earnings
EPS
info
-$3.11
EPS estimate (current quarter)
info
-$0.85
EPS estimate (next quarter)
info
-$0.86
EBITDA
info
$-221M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.02
52-week High
info
$23.19
52-week Low
info
$5.68
50-day moving average
info
$19.53
200-day moving average
info
$15.00
Short ratio
info
14.92
Short %
info
22.44%
Management effectiveness
ROE (TTM)
info
-50.30%
ROA (TTM)
info
-31.36%
Profit margin
info
0.00%
Gross profit margin
info
$18.9M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
61.5M
Float
info
48.1M
Insiders %
info
0.43%
Institutions %
info
112.58%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$33.55
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.77
-$0.89
13.48%
Q3 • 25Beat
-$0.77
-$0.87
11.89%
Q4 • 25Beat
-$0.75
-$0.84
10.71%
Q1 • 26Beat
-$0.81
-$0.71
-14.08%
Q2 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-49.7M
-∞%
Q1 • 26
$0M
$-53.7M
-∞%
Q2 • 26
NaN%
8.14%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$403M
$36.8M
9.13%
Q1 • 26
$364M
$42M
11.55%
Q2 • 26
-9.73%
14.18%
26.49%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-46M
$32.4M
$0.4M
$-46M
Q1 • 26
$-38.2M
$40.7M
$1.1M
$-38.2M
Q2 • 26
-17.00%
25.50%
189.47%
-17.00%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cullinan Oncology LLC share?
Collapse

Cullinan Oncology LLC shares are currently traded for undefined per share.

How many shares does Cullinan Oncology LLC have?
Collapse

Cullinan Oncology LLC currently has 61.5M shares.

Does Cullinan Oncology LLC pay dividends?
Collapse

No, Cullinan Oncology LLC doesn't pay dividends.

What is Cullinan Oncology LLC 52 week high?
Collapse

Cullinan Oncology LLC 52 week high is $23.19.

What is Cullinan Oncology LLC 52 week low?
Collapse

Cullinan Oncology LLC 52 week low is $5.68.

What is the 200-day moving average of Cullinan Oncology LLC?
Collapse

Cullinan Oncology LLC 200-day moving average is $15.00.

Who is Cullinan Oncology LLC CEO?
Collapse

The CEO of Cullinan Oncology LLC is Nadim Ahmed M.S..

How many employees Cullinan Oncology LLC has?
Collapse

Cullinan Oncology LLC has 109 employees.

What is the market cap of Cullinan Oncology LLC?
Collapse

The market cap of Cullinan Oncology LLC is $1.3B.

What is the P/E of Cullinan Oncology LLC?
Collapse

The current P/E of Cullinan Oncology LLC is null.

What is the EPS of Cullinan Oncology LLC?
Collapse

The EPS of Cullinan Oncology LLC is -$3.11.

What is the PEG Ratio of Cullinan Oncology LLC?
Collapse

The PEG Ratio of Cullinan Oncology LLC is null.

What do analysts say about Cullinan Oncology LLC?
Collapse

According to the analysts Cullinan Oncology LLC is considered a buy.